Table 2.

Change in Unspliced Human Immunodeficiency Virus RNA Expression From Baseline to Post-Vorinostat Measurement

	Number of Participants	t Test With Imputation Below Overall LLQ	Longitudinal Censored Model With Participant-Specific LLQ	Negative Binomial Regression
Arm A (vorinostat  +  tamoxifen)	19	1.2 (0.6–2.3)	1.7 (1.1–2.7)	2.4 (1.3–4.6)
Arm B (vorinostat)	8	1.5 (0.7–3.2)	1.5 (0.7–2.9)	2.6 (1.0–6.8)
Ratio between arms		0.8 (0.2–2.4)	1.2 (0.5–2.7)	0.9 (0.3–2.9)

Table shows the fold change and 95% confidence intervals (CIs) of unspliced human immunodeficiency virus RNA expression by study arm, measured as the ratio between expression at 5 hours after the second vorinostat dose compared with baseline, preintervention levels of expression (baseline = incorporates both preentry and entry visit values). The ratio in fold change between arms and 95% CIs are also shown. The fold change was assessed using 3 statistical approaches as detailed in the Methods and Results sections.

Abbreviation: LLQ, lower limit of quantification.